Jinling Pharmaceutical Company Limited (SHE:000919)
China · Delayed Price · Currency is CNY 6.07
-0.14 (-2.25%)
Nov 13, 2026, 3:04 PM CST
SHE:000919 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 3,146 | 3,172 | 3,256 | 3,164 | 2,649 | 2,789 |
Other Revenue | 25.77 | 25.77 | 25.02 | 29.52 | 22.15 | 19.62 |
| 3,172 | 3,197 | 3,281 | 3,194 | 2,671 | 2,809 | |
Revenue Growth | 1.32% | -2.56% | 2.74% | 19.58% | -4.91% | 12.18% |
Cost of Revenue | 2,490 | 2,531 | 2,676 | 2,557 | 2,142 | 2,181 |
Gross Profit | 682.61 | 665.96 | 605.17 | 637.06 | 528.55 | 628.17 |
Selling, General & Admin | 528.23 | 507.86 | 446.73 | 460.88 | 383.48 | 384.3 |
Research & Development | 109.49 | 110.14 | 110.69 | 79.14 | 74.17 | 57.01 |
Other Operating Expenses | 25.52 | 23 | 20.68 | 13 | 18.21 | 19.28 |
Operating Expenses | 658.18 | 641 | 579.86 | 556.22 | 477.52 | 458.93 |
Operating Income | 24.43 | 24.96 | 25.31 | 80.84 | 51.03 | 169.24 |
Interest Expense | -5.12 | -5.21 | -2.2 | -1.3 | -0.26 | -0.29 |
Interest & Investment Income | 44.91 | 49.38 | 63.91 | 58.14 | 34.98 | 46.4 |
Currency Exchange Gain (Loss) | 0.01 | 0.01 | 0.04 | 0.02 | 0.08 | -0 |
Other Non Operating Income (Expenses) | 8.65 | 8.4 | 1.73 | -1.07 | -1.45 | -1.42 |
EBT Excluding Unusual Items | 72.87 | 77.54 | 88.8 | 136.63 | 84.38 | 213.92 |
Impairment of Goodwill | -18.05 | -18.05 | -86.3 | - | - | -45.97 |
Gain (Loss) on Sale of Investments | -6.3 | -0.11 | 14.39 | -0.96 | -27.14 | -29.95 |
Gain (Loss) on Sale of Assets | 4.44 | -0.39 | 21.34 | -0.56 | 61.83 | 51.98 |
Asset Writedown | -0.91 | -0.91 | -10.01 | -0.15 | - | -1.56 |
Other Unusual Items | 3.37 | 7.1 | 11.8 | 13.4 | 8.71 | 6.38 |
Pretax Income | 55.44 | 65.19 | 40.01 | 148.36 | 127.77 | 194.81 |
Income Tax Expense | 11.76 | 13.9 | 22.05 | 19.6 | 13.9 | 41.88 |
Earnings From Continuing Operations | 43.68 | 51.29 | 17.95 | 128.76 | 113.87 | 152.94 |
Minority Interest in Earnings | 0.75 | 2.62 | 22.46 | -22.57 | -8.58 | -32.31 |
Net Income | 44.43 | 53.91 | 40.41 | 106.19 | 105.28 | 120.63 |
Net Income to Common | 44.43 | 53.91 | 40.41 | 106.19 | 105.28 | 120.63 |
Net Income Growth | 38.37% | 33.42% | -61.95% | 0.87% | -12.72% | 85.19% |
Shares Outstanding (Basic) | 622 | 622 | 593 | 504 | 504 | 504 |
Shares Outstanding (Diluted) | 622 | 622 | 593 | 504 | 504 | 504 |
Shares Change | 0.43% | 4.95% | 17.56% | 0.01% | -0.02% | -0.01% |
EPS (Basic) | 0.07 | 0.09 | 0.07 | 0.21 | 0.21 | 0.24 |
EPS (Diluted) | 0.07 | 0.09 | 0.07 | 0.21 | 0.21 | 0.24 |
EPS Growth | 37.77% | 27.13% | -67.63% | 0.86% | -12.70% | 85.22% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 154.86 | 16.34 | -47.44 | -25.85 | -49.05 | 129.26 |
Free Cash Flow Per Share | 0.25 | 0.03 | -0.08 | -0.05 | -0.10 | 0.26 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | 0.100 | 0.100 |
Dividend Growth | 0% | 0% | 0% | 0% | 0% | 0% |
Gross Margin | 21.52% | 20.83% | 18.44% | 19.95% | 19.79% | 22.36% |
Operating Margin | 0.77% | 0.78% | 0.77% | 2.53% | 1.91% | 6.02% |
Profit Margin | 1.40% | 1.69% | 1.23% | 3.33% | 3.94% | 4.29% |
Free Cash Flow Margin | 4.88% | 0.51% | -1.45% | -0.81% | -1.84% | 4.60% |
EBITDA | 159.29 | 168.35 | 180.06 | 229.81 | 173.57 | 291.14 |
EBITDA Margin | 5.02% | 5.27% | 5.49% | 7.20% | 6.50% | 10.37% |
D&A For EBITDA | 134.86 | 143.38 | 154.75 | 148.97 | 122.54 | 121.9 |
EBIT | 24.43 | 24.96 | 25.31 | 80.84 | 51.03 | 169.24 |
EBIT Margin | 0.77% | 0.78% | 0.77% | 2.53% | 1.91% | 6.02% |
Effective Tax Rate | 21.21% | 21.32% | 55.12% | 13.21% | 10.88% | 21.50% |
Revenue as Reported | 3,172 | 3,197 | 3,281 | 3,194 | 2,671 | 2,809 |